ABVC BioPharma, Inc. (NASDAQ:ABVC) Short Interest Down 59.6% in April

ABVC BioPharma, Inc. (NASDAQ:ABVC) was the target of a significant decrease in short interest during the month of April. As of April 15th, there was short interest totalling 533,000 shares, a decrease of 59.6% from the March 31st total of 1,320,000 shares. Based on an average trading volume of 946,600 shares, the short-interest ratio is currently 0.6 days. Currently, 6.1% of the company’s shares are sold short.

ABVC BioPharma Price Performance

Shares of ABVC stock opened at $1.42 on Friday. The business’s 50 day simple moving average is $1.21 and its 200 day simple moving average is $1.25. ABVC BioPharma has a one year low of $0.67 and a one year high of $9.60. The stock has a market capitalization of $15.00 million, a PE ratio of -0.58 and a beta of 0.75.

ABVC BioPharma (NASDAQ:ABVC) last posted its quarterly earnings results on Wednesday, March 13th. The company reported ($0.35) earnings per share (EPS) for the quarter. ABVC BioPharma had a negative return on equity of 226.65% and a negative net margin of 6,919.08%.

ABVC BioPharma Company Profile

ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.